HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice.

AbstractOBJECTIVE:
The circulating irisin increases energy expenditure and improves insulin resistance in mice and humans. The improvement of insulin resistance ameliorates atherosclerosis. Therefore, we hypothesized that irisin alleviates atherosclerosis in diabetes.
METHODS:
Endothelial function was measured by acetylcholine-induced endothelium-dependent vasodilation using aortic rings in apolipoprotein E-Null (apoE(-/-)) streptozotocin-induced diabetic mice. Atherosclerotic lesion was evaluated by plaque area and inflammatory response in aortas. In addition, the endothelium-protective effects of irisin were also further investigated in primary human umbilical vein endothelial cells (HUVECs) in vitro.
RESULTS:
The in vivo experiments showed that irisin treatment significantly improved endothelial dysfunction, decreased endothelial apoptosis, and predominantly decreased atherosclerotic plaque area of both en face and cross sections when compared with normal saline-treated diabetic mice. Moreover, the infiltrating macrophages and T lymphocytes within plaque and the mRNA expression levels of inflammatory cytokines in aortas were also significantly reduced by irisin treatment in mice. The in vitro experiments revealed that irisin inhibited high glucose-induced apoptosis, oxidative stress and increased antioxidant enzymes expression in HUVECs, and pretreatment with LY294002, l-NAME, AMPK-siRNA or eNOS-siRNA, attenuated the protection of irisin on HUVECs apoptosis induced by high glucose. In addition, the in vivo and in vitro experiments showed that irisin increased the phosphorylation of AMPK, Akt and eNOS in aortas and cultured HUVECs.
CONCLUSIONS:
The present study indicates that systemic administration of irisin may be protected against endothelial injury and ameliorated atherosclerosis in apoE(-/-) diabetic mice. The endothelium-protective action of irisin was through activation of AMPK-PI3K-Akt-eNOS signaling pathway. Irisin could be therapeutic for atherosclerotic vascular diseases in diabetes.
AuthorsJunyan Lu, Guangda Xiang, Min Liu, Wen Mei, Lin Xiang, Jing Dong
JournalAtherosclerosis (Atherosclerosis) Vol. 243 Issue 2 Pg. 438-48 (Dec 2015) ISSN: 1879-1484 [Electronic] Ireland
PMID26520898 (Publication Type: Journal Article)
CopyrightCopyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • Apolipoproteins E
  • Cytokines
  • Fibronectins
  • Protein Kinase Inhibitors
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III
  • Proto-Oncogene Proteins c-akt
  • AMP-Activated Protein Kinases
Topics
  • AMP-Activated Protein Kinases (antagonists & inhibitors, genetics, metabolism)
  • Animals
  • Apolipoproteins E (deficiency, genetics)
  • Apoptosis (drug effects)
  • Atherosclerosis (genetics, metabolism, pathology, physiopathology, prevention & control)
  • Cells, Cultured
  • Cytokines (genetics, metabolism)
  • Cytoprotection
  • Diabetes Mellitus, Experimental (drug therapy, genetics, metabolism, pathology, physiopathology)
  • Diabetic Angiopathies (genetics, metabolism, pathology, physiopathology, prevention & control)
  • Endothelial Cells (drug effects, metabolism, pathology)
  • Endothelium, Vascular (drug effects, metabolism, pathology, physiopathology)
  • Fibronectins (pharmacology)
  • Genetic Predisposition to Disease
  • Human Umbilical Vein Endothelial Cells (drug effects, metabolism, pathology)
  • Macrophages (drug effects, metabolism)
  • Male
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Nitric Oxide Synthase Type III (antagonists & inhibitors, genetics, metabolism)
  • Oxidative Stress (drug effects)
  • Phenotype
  • Phosphorylation
  • Plaque, Atherosclerotic
  • Protein Kinase Inhibitors (pharmacology)
  • Proto-Oncogene Proteins c-akt (antagonists & inhibitors, metabolism)
  • RNA Interference
  • Signal Transduction (drug effects)
  • T-Lymphocytes (drug effects, metabolism)
  • Transfection
  • Vasodilation (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: